Skip to main content

LIVE

CGEM

Cullinan Therapeutics, Inc.

CGEM

NASDAQ·Healthcare·Biotechnology·Mkt cap $1.4B

$22.09

-0.32%

P/E

-6.55

Mkt Cap

$1.4B

52-Wk Range

$5.68–$23.19

52-Week Range

$5.68 - $23.19

P/E

-6.55

Fwd P/E

-6.96

Beta

-0.01

Div Yield

0.00%

Avg Vol

934.4K

Shares Out

60.5M

Mkt Cap

$1.4B

Price action

Price chart

Up 222.9% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

3 reasons

  • Experienced founding team led by renowned scientist Patrick A. Baeuerle
  • Diversified pipeline targeting multiple cancer pathways and mechanisms
  • Focus on immuno-oncology, a high-growth area in cancer therapeutics

Bear Case

1 risk

  • Low volatility (beta 0.0).

Growth

Stable outlook

Advancement of clinical-stage candidates through development milestones

Value

Deep value opportunity - significant discount to Healthcare Distribution peers

Momentum

Hot

+66.3% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 5, 2026

Q3 26 RECAP

AUG 6, 2026

Reported EPS of -$0.81 vs -$0.80 consensus (-1.3% surprise).

EPS miss

EPS surprise · last 4Q

0 of 1 beats

Estimate

Actual

Q3 26

-1.3%

Revenue trend · last 8Q

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

Wall Street consensus

3 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

3

100%

Hold

0%

Sell

0%

Median Price Target

Latest: BTIG · Jul 29, 2026

vs Industry

How CGEM stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.